Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by O. Anak
Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Real-World Bendamustine Use in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R Dlbcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cd19-Directed Car T Cell Therapy (Ctl019) for Relapsed/Refractory Diffuse Large B-Cell and Follicular Lymphomas: Four Year Outcomes
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
Annals of Hematology
Medicine
Hematology
Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental